Clinical Trials
39 trialsNCT02123758 2026-06-05
A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
Aragon Pharmaceuticals, Inc.
Phase 1 Active not recruiting
NCT02257736 2026-06-05
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT03748641 2026-06-05
MAGNITUDE
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT04497844 2026-06-05
AMPLITUDE
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT04577833 2026-06-05
A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT04662580 2026-06-05
ARX517
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT05818683 2026-06-05
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT07213674 2026-06-04
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Amgen
Phase 3 Recruiting
NCT03419234 2026-06-03
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT06136650 2026-06-03
MK-5684-004
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT03732820 2026-06-02
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
AstraZeneca
Phase 3 Active not recruiting
NCT06632977 2026-06-02
PREDICT
Alliance for Clinical Trials in Oncology
Phase 2 Recruiting
NCT07198633 2026-06-02
A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 1/2 Recruiting
NCT03012321 2026-06-01
Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
Northwestern University
Phase 2 Active not recruiting
NCT05367440 2026-06-01
PETRANHA
AstraZeneca
Phase 1/2 Active not recruiting
NCT07611110 2026-05-28
VECTRA-01
AstraZeneca
Phase 3 Recruiting
NCT06120491 2026-05-27
EvoPAR-PR01
AstraZeneca
Phase 3 Active not recruiting
NCT04947254 2026-05-15
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03431350 2026-05-11
QUEST
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT05689021 2026-05-11
CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations
Mayo Clinic
Phase 2 Active not recruiting
NCT06212583 2026-05-06
KNIGHTS
University of Maryland, Baltimore
Phase 2 Active not recruiting
NCT04493853 2026-05-05
CAPItello-281
AstraZeneca
Phase 3 Active not recruiting
NCT06136624 2026-05-05
OMAHA-003
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT04194554 2026-05-01
ASCLEPIuS
University of Michigan Rogel Cancer Center
Phase 1/2 Active not recruiting
NCT07005154 2026-05-01
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Astellas Pharma Inc
Phase 2 Recruiting
NCT03436654 2026-04-27
Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05588609 2026-04-27
Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers
Partner Therapeutics, Inc.
Phase 2 Terminated
NCT03706365 2026-04-24
CYCLONE 2
Eli Lilly and Company
Phase 2/3 Active not recruiting
NCT06785636 2026-04-24
P300
Pathos AI, Inc.
Phase 1/2 Recruiting
NCT05457257 2026-04-21
Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations
AstraZeneca
Phase 4 Active not recruiting
NCT02913196 2026-04-20
Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC
Weill Medical College of Cornell University
Phase 1 Completed
NCT06378866 2026-04-20
DIVINE
Mayo Clinic
Phase 2 Recruiting
NCT03821792 2026-04-15
Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02960022 2026-04-13
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Astellas Pharma Inc
Phase 2 Recruiting
NCT06392841 2026-04-08
HARMONY
Hoosier Cancer Research Network
Phase 2 Withdrawn
NCT05593497 2026-03-27
SNARE
VA Office of Research and Development
Phase 2 Recruiting
NCT06421935 2026-03-24
M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)
EMD Serono
Phase 1 Active not recruiting
NCT06457919 2026-03-24
A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT03360721 2026-03-16
Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated